Stock Forecast

  Cardiol Therapeutics Inc. ( CRDL) Stock. Should you Buy or Sell?    $ 1.15

-0.02 (-1.77 %)



Cardiol Therapeutics Inc. Analysis

Updated on 10-09-2022
Symbol CRDL
Price $1.15
Beta 0.924
Volume Avg. $147.66 thousand
Market Cap $71.23 M
52 Week Range $1.0 - $4.96


Cardiol Therapeutics Inc. opened the day at $1.15 which is -1.77 % on yesterday's close. Cardiol Therapeutics Inc. has a 52 week high of $4.96 and 52 week low of $1.0, which is a difference of $3.96. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $71.23 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Cardiol Therapeutics Inc. for $71.23 M, it would take 15 years to get your money back. Cardiol Therapeutics Inc. are in the Drug Manufacturers—Specialty & Generic space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Cardiol Therapeutics Inc. Stock Forecast - Is Cardiol Therapeutics Inc. a Buy or Sell?


DCF Score
ROE Score
ROA Score
DE Score
PE Score
PB Score
Overall Recommendation

Growth and Value


PE Ratio 0.000
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Cardiol Therapeutics Inc.


Price Book Value Ratio 0.000 Price To Book Ratio 0.000
Price To Sales Ratio 0.000 Price Earnings Ratio 0.000


How liquid is Cardiol Therapeutics Inc.


Current Ratio 0.000
Quick Ratio 0.000


Debt


Debt Ratio 0.000 Debt Equity Ratio 0.000
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about Cardiol Therapeutics Inc.


Cardiol Therapeutics says first patient enrolled in acute myocarditis trial of its oral cannabinoid formulation CardiolRx

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc. announced that the first patient has been enrolled in ARCHER, a Phase 2 trial designed to study the safety and tolerability of the oral cannabinoid formulation CardiolRx in patients with acute myocarditis.

Date : 03/08/2022

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 28, 2022, at 4:30 p.m. EDT. Cardiol Therapeutics 2022...

Date : 27/06/2022

Cardiol Therapeutics appoints Teri Loxam and CFO Chris Waddick to its board of directors

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc., the clinical-stage life sciences company, said it has appointed Teri Loxam and its chief financial officer Chris Waddick to serve as board directors, effective immediately.  Loxam has over 25 years of experience in the pharmaceutical, life sciences, and entertainment industries, while Waddick has over 30 years of experience in financial and executive roles in the biotechnology and energy industries, the company said.

Date : 19/05/2022

Cardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced that the US Food and Drug Administration has authorized its Investigational New Drug Application to start its Phase II open-label pilot study. The study will evaluate the tolerance and safety of Cardiol's lead drug CardiolRx, a pharmaceutically-manufactured oral cannabidiol formulation for patients with recurrent pericarditis.

Date : 17/05/2022

Cardiol Therapeutics looks ahead to busy 2022 as it advances new treatment options for cardiovascular disease

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors that the clinical-stage life sciences company is “well positioned” to pursue the development of new treatment options for patients living with heart disease. In a look back at its 2021 year, Elsley said the firm accomplished “several important goals” related to the development of its pharmaceutically produced cannabidiol formulations for use as an anti-fibrotic and anti-inflammatory therapy in cardiovascular disease.

Date : 24/03/2022





About Cardiol Therapeutics Inc.


CEO :
Sector : Healthcare
Industry : Drug Manufacturers—Specialty & Generic

Website : https://www.cardiolrx.com

Exchange : NASDAQ Capital Market

Description :

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.


My Newsletter

Sign Up For Updates & Newsletters